<DOC>
	<DOC>NCT02296892</DOC>
	<brief_summary>A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open label arm for midazolam, in patients undergoing a bronchoscopy.</brief_summary>
	<brief_title>A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>Patients scheduled to undergo a diagnostic or therapeutic fiberoptic bronchoscopy in the bronchoscopy suite (e.g. lavage, biopsies, brushings, foreign body extraction) Bronchoscopy outside the bronchoscopy suite (e.g. Intensive Care Unit) SpO2 &lt; 90% in ambient air, or patients on chronic continuous O2 support or on mechanical ventilation Forced expiratory volume (FEV1) &lt; 1L Tracheal stenosis Planned laser bronchoscopy, rigid scope bronchoscopy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>